Clinical evidence of statin therapy in non-dyslipidemic disorders

Pharmacological Research

Volumn 88, Issue , 2014, Pages 20-30

  Ferri, Nicola ^a   Corsini, Alberto ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Liver diseases; Macular degeneration; Polycystic ovary syndrome; Rheumatoid arthritis; Statins; Venous thromboembolism

Indexed keywords

ANTIVITAMIN K; ATORVASTATIN; CERIVASTATIN; FENOFIBRATE; FLUINDOSTATIN; FONDAPARINUX; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW MOLECULAR WEIGHT HEPARIN; METFORMIN; MEVALONIC ACID; PLACEBO; PRAVASTATIN; RHEUMATOID FACTOR; ROSUVASTATIN; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; BLOOD CLOTTING; CHOLESTEROL SYNTHESIS; DEEP VEIN THROMBOSIS; DISEASE ACTIVITY; DISEASE DURATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; ERYTHROCYTE SEDIMENTATION RATE; FATTY LIVER; HEART PROTECTION; HUMAN; HYPERANDROGENISM; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMMUNOMODULATION; ISCHEMIC HEART DISEASE; LIVER DISEASE; LOW DRUG DOSE; LUNG EMBOLISM; NONALCOHOLIC FATTY LIVER; OVARY POLYCYSTIC DISEASE; PLEIOTROPY; PRIMARY PREVENTION; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; SECONDARY PREVENTION; STEROIDOGENESIS; VENOUS THROMBOEMBOLISM; VISUAL ANALOG SCALE; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; FEMALE; LIVER DISEASES; MACULAR DEGENERATION; POLYCYSTIC OVARY SYNDROME;

ANIMALS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER DISEASES; MACULAR DEGENERATION; MEVALONIC ACID; POLYCYSTIC OVARY SYNDROME; VENOUS THROMBOEMBOLISM;

EID: 84906791353     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2014.02.003     Document Type: Review

References (125)

1. T.P. Bersot Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12e Drug Therapy for Hypercholesterolemia and Dyslipidemia 31 2011 892 898
2. B. Mihaylova, J. Emberson, L. Blackwell, A. Keech, J. Simes, and E.H. Barnes et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
3. C. Baigent, L. Blackwell, J. Emberson, L.E. Holland, C. Reith, and N. Bhala et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
4. S. Bellosta, N. Ferri, L. Arnaboldi, F. Bernini, R. Paoletti, and A. Corsini Pleiotropic effects of statins in atherosclerosis and diabetes Diabetes Care 23 Suppl. 2 2000 B72 B78
5. A. Tawakol, Z.A. Fayad, R. Mogg, A. Alon, M.T. Klimas, and H. Dansky et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose- positron emission tomography/computed tomography feasibility study J Am Coll Cardiol 62 2013 909 917
6. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., and J.J. Kastelein et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Lancet 373 2009 1175 1182
7. N. Ferri, G. Colombo, C. Ferrandi, E.W. Raines, B. Levkau, and A. Corsini Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation Arterioscler Thromb Vasc Biol 27 2007 1043 1049 (Pubitemid 46641955)
8. A.L. Bishopand, and A. Hall Rho GTPases and their effector proteins Biochem J 348 Pt 2 2000 241 255 (Pubitemid 30345195)
9. S. Etienne-Mannevilleand, and A. Hall Rho GTPases in cell biology Nature 420 2002 629 635 (Pubitemid 36764489)
10. A. Corsini, N. Ferri, and M. Cortellaro Are pleiotropic effects of statins real? Vasc Health Risk Manag 3 2007 611 613 (Pubitemid 350104116)
11. C. Bolchi, M. Pallavicini, S.K. Bernini, G. Chiodini, A. Corsini, and N. Ferri et al. Thiazole- and imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase Bioorg Med Chem Lett 21 2011 5408 5412
12. S. Bellosta, N. Ferri, F. Bernini, R. Paoletti, and A. Corsini Non-lipid-related effects of statins Ann Med 32 2000 164 176 (Pubitemid 30237561)
13. P. Gazzerro, M.C. Proto, G. Gangemi, A.M. Malfitano, E. Ciaglia, and S. Pisanti et al. Pharmacological actions of statins: a critical appraisal in the management of cancer Pharmacol Rev 64 2012 102 146
14. A.M. Abelesand, and M.H. Pillinger Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy? Arthritis Rheum 54 2006 393 407 (Pubitemid 43228614)
15. I.D. del Rincon, K. Williams, M.P. Stern, G.L. Freeman, and A. Escalante High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors Arthritis Rheum 44 2001 2737 2745 (Pubitemid 34016192)
16. D.H. Solomon, E.W. Karlson, E.B. Rimm, C.C. Cannuscio, L.A. Mandl, and J.E. Manson et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis Circulation 107 2003 1303 1307 (Pubitemid 36314415)
17. M.J. Kaplanand, and W.J. McCune New evidence for vascular disease in patients with early rheumatoid arthritis Lancet 361 2003 1068 1069 (Pubitemid 36369555)
18. S. Cobb, F. Anderson, and W. Bauer Length of life and cause of death in rheumatoid arthritis N Engl J Med 249 1953 553 556
19. S. Schneeweiss, S. Setoguchi, M.E. Weinblatt, J.N. Katz, J. Avorn, and P.E. Sax et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis Arthritis Rheum 56 2007 1754 1764 (Pubitemid 47110375)
20. V. Pasceriand, and E.T. Yeh A tale of two diseases: atherosclerosis and rheumatoid arthritis Circulation 100 1999 2124 2126
21. J.A. Avina-Zubieta, H.K. Choi, M. Sadatsafavi, M. Etminan, J.M. Esdaile, and D. Lacaille Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies Arthritis Rheum 59 2008 1690 1697
22. M.J. Peters, D.P. Symmons, D. McCarey, B.A. Dijkmans, P. Nicola, and T.K. Kvien et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis Ann Rheum Dis 69 2010 325 331
23. C. Turesson, W.M. O'Fallon, C.S. Crowson, S.E. Gabriel, and E.L. Matteson Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis J Rheumatol 29 2002 62 67 (Pubitemid 34041860)
24. T.E. Toms, V.F. Panoulas, K.M. Douglas, H. Griffiths, N. Sattar, and J.P. Smith et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis 69 2010 683 688
25. M.M. Goyochea-Robles, and C.H. Rahman Compliance with statin therapy in rheumatoid arthritis in patients Arthritis Rheum 59 2008 S877
26. M.A. De Vera, H. Choi, M. Abrahamowicz, J. Kopec, M.V. Goycochea-Robles, and D. Lacaille Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study Ann Rheum Dis 70 2011 1020 1024
27. M.A. De Vera, H. Choi, M. Abrahamowicz, J. Kopec, and D. Lacaille Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study Arthritis Care Res (Hoboken) 64 2012 809 816
28. E. Myasoedova, C.S. Crowson, H.M. Kremers, V.L. Roger, P.D. Fitz-Gibbon, and T.M. Therneau et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease Ann Rheum Dis 70 2011 482 487
29. X. Sheng, M.J. Murphy, T.M. Macdonald, and L. Wei Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis J Rheumatol 39 2012 32 40
30. E. Myasoedova, S.E. Gabriel, A.B. Green, E.L. Matteson, and C.S. Crowson The impact of statin use on lipid levels in statin-naive patients with rheumatoid arthritis (RA) vs. non-RA subjects: results from a population-based study Arthritis Care Res (Hoboken) 65 2013 1592 1599
31. A.G. Semb, I. Holme, T.K. Kvien, and T.R. Pedersen Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial Rheumatology (Oxford) 50 2001 324 329
32. A.G. Semb, T.K. Kvien, D.A. DeMicco, R. Fayyad, C.C. Wun, and J.C. LaRosa et al. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease Arthritis Rheum 64 2012 2836 2846
33. D.W. McCarey, I.B. McInnes, R. Madhok, R. Hampson, O. Scherbakov, and I. Ford et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial Lancet 363 2004 2015 2021 (Pubitemid 38781100)
34. J. Lindhardsen, O. Ahlehoff, G.H. Gislason, O.R. Madsen, J.B. Olesen, and C. Torp-Pedersen et al. Initiation and adherence to secondary prevention pharmacotherapy after myocardial infarction in patients with rheumatoid arthritis: a nationwide cohort study Ann Rheum Dis 71 2012 1496 1501
35. T.T. Tang, Y. Song, Y.J. Ding, Y.H. Liao, X. Yu, and R. Du et al. Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis J Lipid Res 52 2011 1023 1032
36. R. Ghittoni, G. Napolitani, D. Benati, C. Ulivieri, L. Patrussi, and F. Laghi Pasini et al. Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases Eur J Immunol 36 2006 2885 2893 (Pubitemid 44782562)
37. S.E. Dunn, S. Youssef, M.J. Goldstein, T. Prod'homme, M.S. Weber, and S.S. Zamvil et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin J Exp Med 203 2006 401 412 (Pubitemid 43290849)
38. B.P. Leung, N. Sattar, A. Crilly, M. Prach, D.W. McCarey, and H. Payne et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis J Immunol 170 2003 1524 1530 (Pubitemid 36139524)
39. T. Yamagata, K. Kinoshita, Y. Nozaki, M. Sugiyama, S. Ikoma, and M. Funauchi Effects of pravastatin in murine collagen-induced arthritis Rheumatol Int 27 2007 631 639 (Pubitemid 46625346)
40. H. Okamoto, K. Koizumi, S. Kamitsuji, E. Inoue, M. Hara, and T. Tomatsu et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort J Rheumatol 34 2007 964 968 (Pubitemid 46774839)
41. H. Kanda, K. Hamasaki, K. Kubo, S. Tateishi, A. Yonezumi, and Y. Kanda et al. Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis J Rheumatol 29 2002 2024 2026 (Pubitemid 34988721)
42. M. Goto A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis Mod Rheumatol 20 2010 238 243
43. L. Cojocaru, A.C. Rusali, C. Suta, A.M. Radulescu, M. Suta, and E. Craiu The role of simvastatin in the therapeutic approach of rheumatoid arthritis Autoimmune Dis 2013 2013 326258
44. S. Lodi, S.J. Evans, P. Egger, and J. Carpenter Is there an anti-inflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database Br J Clin Pharmacol 69 2010 85 94
45. E.E. Arts, T.L. Jansen, A. Den Broeder, H.E. Vonkeman, E. Dutmer, and M.A. Van de Laar et al. Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry Ann Rheum Dis 70 2011 877 878
46. G. Chodick, H. Amital, Y. Shalem, E. Kokia, A.D. Heymann, and A. Porath et al. Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study PLoS Med 7 2010 e1000336
47. S.S. Jick, H. Choi, L. Li, I.B. McInnes, and N. Sattar Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis Ann Rheum Dis 68 2009 546 551
48. A. Garcia-Martinez, J. Hernandez-Rodriguez, J.M. Grau, and M.C. Cid Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis Arthritis Rheum 51 2004 674 678 (Pubitemid 39056259)
49. D.G. Hackam, M. Mamdani, P. Li, and D.A. Redelmeier Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis Lancet 367 2006 413 418 (Pubitemid 43184262)
50. S. Setoguchi, J. Avorn, and S. Schneeweiss Statins and the risk of colorectal cancer N Engl J Med 353 2005 952 954 [author reply 952-954]
51. P. Prandoni, A. Ghirarduzzi, M.H. Prins, V. Pengo, B.L. Davidson, and H. Sorensen et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis J Thromb Haemost 4 2006 1891 1896 (Pubitemid 44226764)
52. S. Colli, S. Eligini, M. Lalli, M. Camera, R. Paoletti, and E. Tremoli Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis Arterioscler Thromb Vasc Biol 17 1997 265 272 (Pubitemid 27098183)
53. A. Hilgendorff, H. Muth, B. Parviz, A. Staubitz, W. Haberbosch, and H. Tillmanns et al. Statins differ in their ability to block NF-kappaB activation in human blood monocytes Int J Clin Pharmacol Ther 41 2003 397 401 (Pubitemid 37138482)
54. R. Baetta, M. Camera, C. Comparato, C. Altana, M.D. Ezekowitz, and E. Tremoli Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering Arterioscler Thromb Vasc Biol 22 2002 692 698 (Pubitemid 34408755)
55. F. Bea, E. Blessing, M.I. Shelley, J.M. Shultz, and M.E. Rosenfeld Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation Arteriosclerosis 167 2003 187 194 (Pubitemid 36773519)
56. M. Monetti, M. Canavesi, M. Camera, R. Parente, R. Paoletti, and E. Tremoli et al. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice Pharmacol Res 55 2007 441 449 (Pubitemid 46560397)
57. A. Undas, M. Celinska-Lowenhoff, T.B. Domagala, T. Iwaniec, J. Dropinski, and T. Lowenhoff et al. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia Thromb Haemost 94 2005 193 199 (Pubitemid 40974724)
58. A. Szczeklik, J. Musial, A. Undas, P. Gajewski, P. Gora, and J. Swadzba et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia J Am Coll Cardiol 33 1999 1286 1293
59. J.G. Ray, M. Mamdani, R.T. Tsuyuki, D.R. Anderson, E.L. Yeo, and A. Laupacis Use of statins and the subsequent development of deep vein thrombosis Arch Intern Med 161 2001 1405 1410 (Pubitemid 32681161)
60. A.S. Ramcharan, K.J. Van Stralen, J.D. Snoep, A.K. Mantel-Teeuwisse, F.R. Rosendaal, and C.J. Doggen HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis J Thromb Haemost 7 2009 514 520
61. D.M. Herrington, E. Vittinghoff, F. Lin, J. Fong, F. Harris, and D. Hunninghake et al. Statin therapy, cardiovascular events, and total mortality in the heart and estrogen/progestin replacement study (HERS) Circulation 105 2002 2962 2967 (Pubitemid 34693827)
62. H.T. Sorensen, E. Horvath-Puho, K.K. Sogaard, S. Christensen, S.P. Johnsen, and R.W. Thomsen et al. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study J Thromb Haemost 7 2009 521 528
63. K. Lacut, G. Le Gal, J.H. Abalain, D. Mottier, and E. Oger Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia? Thromb Res 122 2008 314 319 (Pubitemid 351888887)
64. M. Resh, B.K. Mahmoodi, G.J. Navis, N.J. Veeger, and W.M. Lijfering Statin use in patients with nephrotic syndrome is associated with a lower risk of venous thromboembolism Thromb Res 127 2011 395 399
65. L. Smeeth, I. Douglas, A.J. Hall, R. Hubbard, and S. Evans Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials Br J Clin Pharmacol 67 2009 99 109
66. C.C. Yang, S.S. Jick, and H. Jick Statins and the risk of idiopathic venous thromboembolism Br J Clin Pharmacol 53 2002 101 105 (Pubitemid 34117746)
67. M. Pai, N.S. Evans, S.J. Shah, D. Green, D. Cook, and M.A. Crowther Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies Thromb Res 128 2011 422 430
68. R.J. Glynn, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., and J.J. Kastelein et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism N Engl J Med 360 2009 1851 1861
69. A. Squizzato, M. Galli, E. Romualdi, F. Dentali, P.W. Kamphuisen, and L. Guasti et al. Statins, fibrates, and venous thromboembolism: a meta-analysis Eur Heart J 31 2010 1248 1256
70. L. Li, T. Sun, P. Zhang, J. Tian, and K. Yang Statins for primary prevention of venous thromboembolism Cochrane Database Syst Rev 2011 CD008203
71. D.J. Freeman, M. Robertson, E.A. Brown, A. Rumley, E.S. Tobias, and M. Frolich et al. Incident venous thromboembolic events in the prospective study of pravastatin in the elderly at risk (PROSPER) BMC Geriatr 11 2011 8
72. K. Rahimi, N. Bhala, P. Kamphuisen, J. Emberson, S. Biere-Rafi, and V. Krane et al. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials PLoS Med 9 2012 e1001310
73. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group N Engl J Med 339 1998 1349 1357
74. P. Amarenco, J. Bogousslavsky, A. Callahan 3rd, L.B. Goldstein, M. Hennerici, and A.E. Rudolph et al. Prevention by aggressive reduction in cholesterol levels. High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 2006 549 559 (Pubitemid 44202151)
75. H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, and S.J. Livingstone et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696 (Pubitemid 39140624)
76. B. Fellstrom, H. Holdaas, A.G. Jardine, I. Holme, G. Nyberg, and P. Fauchald et al. Effect of fluvastatin on renal end points in the assessment of lescol in renal transplant (ALERT) trial Kidney Int 66 2004 1549 1555 (Pubitemid 39298389)
77. Heart Protection Study Collaborative MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
78. J. Kjekshus, E. Apetrei, V. Barrios, M. Bohm, J.G. Cleland, and J.H. Cornel et al. Rosuvastatin in older patients with systolic heart failure N Engl J Med 357 2007 2248 2261 (Pubitemid 350190755)
79. C. Wanner, V. Krane, W. Marz, M. Olschewski, J.F. Mann, and G. Ruf et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 2005 238 248 (Pubitemid 41058323)
80. L. Rabinowich, A. Steinvil, E. Leshem-Rubinow, S. Berliner, D. Zeltser, and O. Rogowski et al. Adherence to statins is associated with reduced incidence of idiopathic venous thromboembolism: real-life data from a large healthcare maintenance organisation Heart 98 2012 1817 1821
81. R.W. Thomsen The lesser known effects of statins: benefits on infectious outcomes may be explained by "healthy user" effect BMJ 333 2006 980 981
82. J. Ludwig, T.R. Viggiano, D.B. McGill, and B.J. Oh Noanalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease Mayo Clin Proc 55 1980 434 438 (Pubitemid 10057164)
83. E. Bugianesi, N. Leone, E. Vanni, G. Marchesini, F. Brunello, and P. Carucci et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma Gastroenterology 123 2002 134 140 (Pubitemid 34747534)
84. C. Soderberg, P. Stal, J. Askling, H. Glaumann, G. Lindberg, and J. Marmur et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up Hepatology 51 2010 595 602
85. W. Nseir, A. Shalata, A. Marmor, and N. Assy Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease Dig Dis Sci 56 2011 3439 3449
86. S. Tandraand, and R. Vuppalanchi Use of statins in patients with liver disease Curr Treat Options Cardiovasc Med 11 2009 272 278
87. D.E. Cohen, F.A. Anania, and N. Chalasani An assessment of statin safety by hepatologists Am J Cardiol 97 2006 77C 81C
88. A. Nelson, D.M. Torres, A.E. Morgan, C. Fincke, and S.A. Harrison A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial J Clin Gastroenterol 43 2009 990 994
89. V.G. Athyros, K. Tziomalos, T.D. Gossios, T. Griva, P. Anagnostis, and K. Kargiotis et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek atorvastatin and coronary heart disease evaluation (GREACE) study: a post-hoc analysis Lancet 376 2010 1916 1922
90. T. Foster, M.J. Budoff, S. Saab, N. Ahmadi, C. Gordon, and A.D. Guerci Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial Am J Gastroenterol 106 2011 71 77
91. C. Pramfalk, P. Parini, U. Gustafsson, S. Sahlin, and M. Eriksson Effects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism J Intern Med 269 2011 333 339
92. R. Klein, B.E. Klein, M.D. Knudtson, M.F. Cotch, T.Y. Wong, and K. Liu et al. Subclinical atherosclerotic cardiovascular disease and early age-related macular degeneration in a multiracial cohort: the Multiethnic Study of Atherosclerosis Arch Ophthalmol 125 2007 534 543 (Pubitemid 46596726)
93. C.A. McCarty, B.N. Mukesh, C.L. Fu, P. Mitchell, J.J. Wang, and H.R. Taylor Risk factors for age-related maculopathy: the visual impairment project Arch Ophthalmol 119 2001 1455 1462 (Pubitemid 32963248)
94. P. Mitchell, W. Smith, K. Attebo, and J.J. Wang Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study Ophthalmology 102 1995 1450 1460
95. M.R. Van Newkirk, M.B. Nanjan, J.J. Wang, P. Mitchell, H.R. Taylor, and C.A. McCarty The prevalence of age-related maculopathy: the visual impairment project Ophthalmology 107 2000 1593 1600
96. R.A. Heuberger, J.A. Mares-Perlman, R. Klein, B.E. Klein, A.E. Millen, and M. Palta Relationship of dietary fat to age-related maculopathy in the Third National Health and Nutrition Examination Survey Arch Ophthalmol 119 2001 1833 1838 (Pubitemid 33139616)
97. J.A. Mares-Perlman, W.E. Brady, R. Klein, G.M. Van den Langenberg, B.E. Klein, and M. Palta Dietary fat and age-related maculopathy Arch Ophthalmol 113 1995 743 748
98. J.M. Seddon, B. Rosner, R.D. Sperduto, L. Yannuzzi, J.A. Haller, and N.P. Blair et al. Dietary fat and risk for advanced age-related macular degeneration Arch Ophthalmol 119 2001 1191 1199 (Pubitemid 32730008)
99. Risk factors for neovascular age-related macular degeneration. The Eye Disease Case-Control Study Group Arch Ophthalmol 110 1992 1701 1708
100. R. Klein, B.E. Klein, S.C. Tomany, L.G. Danforth, and K.J. Cruickshanks Relation of statin use to the 5-year incidence and progression of age-related maculopathy Arch Ophthalmol 121 2003 1151 1155 (Pubitemid 36962169)
101. R. Klein, B.E. Klein, S.C. Jensen, K.J. Cruickshanks, K.E. Lee, and L.G. Danforth et al. Medication use and the 5-year incidence of early age-related maculopathy: the Beaver Dam Eye study Arch Ophthalmol 119 2001 1354 1359 (Pubitemid 32994881)
102. C. Delcourt, F. Michel, A. Colvez, A. Lacroux, M. Delage, and M.H. Vernet Associations of cardiovascular disease and its risk factors with age-related macular degeneration: the POLA study Ophthal Epidemiol 8 2001 237 249 (Pubitemid 32681944)
103. R. van Leeuwen, J.R. Vingerling, A. Hofman, P.T. de Jong, and B.H. Stricker Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement BMJ 326 2003 255 256 (Pubitemid 36169589)
104. C.A. McCarty, B.N. Mukesh, R.H. Guymer, P.N. Baird, and H.R. Taylor Cholesterol-lowering medications reduce the risk of age-related maculopathy progression Med J Aust 175 2001 340 (Pubitemid 32888333)
105. E. Martini, L. Scorolli, M. Burgagni, and S. Fessehaie Evaluation of the retinal effects of simvastatin in patients with agerelated macular degeneration Valutazione degli effetti retinici della somministrazione di simvastatina in pazienti affetti da degenerazione maculare senile Annali Di Ottalmologia e Clinica Oculistica 117 1991 1121 1126
106. R.H. Guymer, P.N. Dimitrov, M. Varsamidis, L.L. Lim, P.N. Baird, and A.J. Vingrys et al. Can HMG Co-A reductase inhibitors ("statins") slow the progression of age-related macular degeneration? The age-related maculopathy statin study (ARMSS) Clin Interv Aging 3 2008 581 593
107. M. Sasaki, W.L. Gan, R. Kawasaki, L. Hodgson, K.Y. Lee, and T.Y. Wong et al. Effect of simvastatin on retinal vascular caliber: the age-related maculopathy statin study Acta Ophthalmol 91 2013 e418 e419
108. D.A. Ehrmann Polycystic ovary syndrome N Engl J Med 352 2005 1223 1236
109. R. Azziz, K.S. Woods, R. Reyna, T.J. Key, E.S. Knochenhauer, and B.O. Yildiz The prevalence and features of the polycystic ovary syndrome in an unselected population J Clin Endocrinol Metab 89 2004 2745 2749 (Pubitemid 38766360)
110. N.K. Stepto, S. Cassar, A.E. Joham, S.K. Hutchison, C.L. Harrison, and R.F. Goldstein et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp Hum Reprod 28 2013 777 784
111. R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, and W. Futterweit et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline J Clin Endocrinol Metab 91 2006 4237 4245 (Pubitemid 44833391)
112. J.C. Lo, S.L. Feigenbaum, J. Yang, A.R. Pressman, J.V. Selby, and A.S. Go Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome J Clin Endocrinol Metab 91 2006 1357 1363
113. A.S. Dobs, H. Schrott, M.H. Davidson, H. Bays, E.A. Stein, and D. Kush et al. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia Metabolism 49 2000 1234 1238
114. L. Gao, F.L. Zhao, and S.C. Li Statin is a reasonable treatment option for patients with polycystic ovary syndrome: a meta-analysis of randomized controlled trials Exp Clin Endocrinol Diabetes 120 2012 367 375
115. T. Sathyapalan, E.S. Kilpatrick, A.M. Coady, and S.L. Atkin The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study J Clin Endocrinol Metab 94 2009 103 108
116. T. Sathyapalan, K.A. Smith, A.M. Coady, E.S. Kilpatrick, and S.L. Atkin Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study Ann Clin Biochem 49 2012 80 85
117. B. Banaszewska, L. Pawelczyk, R.Z. Spaczynski, J. Dziura, and A.J. Duleba Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial J Clin Endocrinol Metab 92 2007 456 461
118. B. Banaszewska, L. Pawelczyk, R.Z. Spaczynski, and A.J. Duleba Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial J Clin Endocrinol Metab 94 2009 4938 4945
119. B. Banaszewska, L. Pawelczyk, R.Z. Spaczynski, and A.J. Duleba Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment J Clin Endocrinol Metab 96 2011 3493 3501
120. C. Kaya, S.D. Cengiz, B. Berker, S. Demirtas, M. Cesur, and G. Erdogan Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study Fertil Steril 92 2009 635 642
121. C. Abud-Mendoza, H. de la Fuente, E. Cuevas-Orta, L. Baranda, J. Cruz-Rizo, and R. Gonzalez-Amaro Therapy with statins in patients with refractory rheumatic diseases: a preliminary study Lupus 12 2003 607 611 (Pubitemid 37021796)
122. C. Tikiz, O. Utuk, T. Pirildar, O. Bayturan, P. Bayindir, and F. Taneli et al. Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis J Rheumatol 32 2005 2095 2101 (Pubitemid 41587851)
123. K.M. Maki-Petaja, A.D. Booth, F.C. Hall, S.M. Wallace, J. Brown, and C.M. McEniery et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis J Am Coll Cardiol 50 2007 852 858 (Pubitemid 47268750)
124. P.S. Sever, B. Dahlof, N.R. Poulter, H. Wedel, G. Beevers, and M. Caulfield et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158 (Pubitemid 36398384)
125. T. Kazerooni, A. Shojaei-Baghini, S. Dehbashi, N. Asadi, F. Ghaffarpasand, and Y. Kazerooni Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study Fertil Steril 94 2010 2208 2213